Dana-Farber Cancer Institute, Inc Patent Portfolio Statistics
Profile Summary
This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.
How does the overall patent portfolio of Dana-Farber Cancer Institute, Inc. look like?
| Assignee | Art Units | |
| Total Applications: | 1,160 | 1,224,192 |
| Granted Patents: | 596 | 539,210 |
| Grant Index | 71.81% ↑ | 62.57% |
| Abandoned/Rejected Applications: | 234 (28.19%) | 322,514 (37.43%) |
| In-Process Applications: | 325 | 362,468 |
| Average Grant Time: | 3.28 Years ↑ | 2.89 Years |
| Average Office Actions: | 2.22 ↑ | 1.79 |
Which Technology Area Dana-Farber Cancer Institute, Inc. is filing most patents in? (Last 10 years)
| Art Unit | Definition | Total Applications |
| 1642 | Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology | 128 |
| 1624 | Organic Chemistry | 74 |
| 1634 | Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry | 71 |
| 1644 | Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology | 61 |
| Opap | Parked GAU | 60 |
How many patents are Dana-Farber Cancer Institute, Inc. filing every year?
| Year | Total Applications | Predicted |
| 2022 | 0* | 219 |
| 2021 | 30* | 259 |
| 2020 | 109 | 229 |
| 2019 | 104 | 104 |
| 2018 | 112 | – |
| 2017 | 110 | – |
| 2016 | 96 | – |
| 2015 | 82 | – |
| 2014 | 53 | – |
| 2013 | 46 | – |
*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published
Recently filed patent applications of Dana-Farber Cancer Institute, Inc. in USPTO?
Application number: 17/641,288
Abstract:
–
Publication date: –
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Constantine Mitsiades S
Publication number: None
Application number: 17/631,774
Abstract:
–
Publication date: –
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Gray Nathanael S
Publication number: None
Application number: 17/620,473
Abstract:
–
Publication date: –
Applicant: Dana-Farber Cancer Institute, Inc.
Inventors: Tinghu Zhang
How are Dana-Farber Cancer Institute, Inc.’s applications performing in USPTO?
| Application Number | Title | Status | Art Unit | Examiner |
| 17/641,288 | Methods For Treating Cancer Using Serial Administration Of E3 Ubiquitin Ligase Degraders | Application Undergoing Preexam Processing | – | – |
| 17/631,774 | Degraders Of Cyclin-Dependent Kinase 7 (Cdk7) And Uses Thereof | Docketed New Case – Ready for Examination | OPAP | Central, Docket |
| 17/620,473 | Small Molecule Inhibitors Of Src Tyrosine Kinase | Docketed New Case – Ready for Examination | OPAP | Central, Docket |
| 17/620,394 | E3 Ligase Binders And Uses Thereof | Docketed New Case – Ready for Examination | OPAP | Central, Docket |
| 17/596,466 | Hdac3 Catalytic Inhibitor Development And Uses Thereof | Application Undergoing Preexam Processing | 1629 | – |
